Immunotherapy Treatment in China (2026): China Approves Drug That Beat Keytruda — What It Means for Patients

Immunotherapy Treatment in China: Complete Cost and Access Guide (2026)

What Is Immunotherapy?

Immunotherapy works by mobilizing the body's own immune system to recognize and destroy cancer cells. The most common form for solid tumors is PD-1/PD-L1 checkpoint inhibition — drugs that block the "off switch" that cancer cells use to hide from immune surveillance. Single-agent PD-1 inhibitors like pembrolizumab (Keytruda) or nivolumab (Opdivo) have been standard-of-care for lung cancer, melanoma, and several other cancers since the mid-2010s.

Bispecific antibodies are the next generation of immunotherapy — engineered molecules that bind to two targets at once. Ivonescimab binds both PD-1 and VEGF (vascular endothelial growth factor). The dual action attacks cancer in two ways: PD-1 releases the immune brake, while VEGF cuts off the tumor's blood supply.

NMPA-Approved Immunotherapy Drugs in China (2026)

China's NMPA has approved more immunotherapy drugs than any other country outside the US, including several not yet available in Europe or the US:

How Much Does Immunotherapy Cost in China?

For international patients paying out of pocket, costs in China are a fraction of US prices:

All prices are estimates for international patients in premium wards at Grade 3A hospitals. Domestic Chinese patients pay significantly less through the national insurance scheme. International patient wards charge higher rates but provide English-language coordination and streamlined admission.

Who Is Eligible for Immunotherapy?

Eligibility depends on the specific drug and indication. General criteria for PD-1/PD-L1 immunotherapy include:

• Confirmed diagnosis of a cancer type with an approved indication for immunotherapy (lung cancer, melanoma, cervical cancer, gastric cancer, bladder cancer, Hodgkin lymphoma, liver cancer, etc.)
• PD-L1 expression levels may be required (for some indications; ivonescimab approved for PD-L1-positive NSCLC regardless of expression level)
• Adequate organ function (liver, kidney, bone marrow) to tolerate treatment
• No active autoimmune disease that would be worsened by immune activation
• ECOG performance status 0–2 (able to carry out normal daily activities with varying degrees of assistance)

China's Immunotherapy Advantages for International Patients

• Access to drugs unavailable at home: Ivonescimab and cadonilimab are not approved in the US, EU, or most Asian markets. Some patients have no equivalent option in their home country.
• Significant cost savings: Even with flights, accommodation, and translation services, total treatment costs in China are typically 50–80% lower than equivalent care in the US.
• Fast treatment start: No insurance pre-authorization bureaucracy. International patients can often begin treatment within a week of arrival.
• High treatment volumes: Chinese Grade 3A hospitals handle large numbers of immunotherapy patients, building clinical expertise that matches or exceeds most Western centers for specific drug indications.
• Bridging therapy options: Patients already on treatment in their home country may be able to continue or transition to domestic PD-1 inhibitors under the supervision of a Chinese oncologist.

Top Hospitals for Immunotherapy in China

These hospitals have established international patient departments and active oncology programs with immunotherapy:

• Guangzhou Academy of Sciences Renmin Hospital — High-volume immunotherapy center with experience across multiple cancer types; active international patient ward
• Shanghai Ruijin Hospital — Leading hematology and oncology center; one of China's most active CAR-T and immunotherapy trial sites
• Beijing Cancer Hospital — One of China's foremost cancer centers with access to the latest NMPA-approved immunotherapy drugs
• Peking University Cancer Hospital — Extensive experience with immunotherapy combinations for lung, gastric, and cervical cancers
• Tongji Hospital, Shanghai — Strong oncology department with domestic PD-1 inhibitor programs and international patient services

The Treatment Process: Timeline and What to Expect

Immunotherapy in China typically requires a shorter stay than cell therapies like CAR-T. Most international patients plan for 1–3 cycles over 3–6 weeks, with treatment repeated every 3–4 weeks:

• Pre-arrival: Submit medical records, pathology reports, and PD-L1 test results. The hospital reviews and provides a preliminary treatment plan and cost estimate within 48–72 hours.
• Day 1 (arrival): Initial consultation with the oncology team, physical examination, and baseline bloodwork. Treatment plan is confirmed.
• Days 2–5: First immunotherapy infusion. Most PD-1/PD-L1 inhibitors are given as a 30–60 minute IV infusion. Patients are monitored for 2–4 hours post-infusion for cytokine release reactions.
• Pre-discharge assessment: Blood tests and imaging review before departure. The medical team provides a follow-up schedule for home-country monitoring.
• Ongoing cycles: Subsequent cycles can often be arranged at a local hospital in your home country, with your Chinese oncologist coordinating remotely with your local team.

China vs US: Immunotherapy Cost Comparison (2026)

Patient Decision Guide: Is Immunotherapy in China Right for You?

Who Should Consider Immunotherapy in China

• Patients whose cancer type has an approved indication for PD-1/PD-L1 immunotherapy but whose home country's formulary does not include a specific drug — particularly bispecific antibodies like ivonescimab or cadonilimab
• Patients facing long wait times for treatment start due to insurance pre-authorization or drug availability issues in their home country
• Patients seeking to reduce out-of-pocket treatment costs by 50–80% compared to US prices
• Patients with cancer types where domestic Chinese PD-1 inhibitors have shown strong efficacy (certain lung, gastric, and liver cancers)
• Patients who have exhausted standard-of-care options and are looking for next-generation drugs available in China but not elsewhere

Who Should NOT Come to China for Immunotherapy

• Patients with active autoimmune disease (lupus, rheumatoid arthritis, inflammatory bowel disease) who are on immunosuppressing drugs — immunotherapy can reactivate autoimmune conditions
• Patients with extensive organ dysfunction (severe liver cirrhosis, end-stage kidney disease) who cannot tolerate treatment
• Patients whose cancers are driven by specific mutations better treated with targeted therapy (EGFR-mutant NSCLC with osimertinib, BRAF-mutant melanoma with dabrafenib/trametinib) — immunotherapy is not first-line for these subgroups
• Patients who cannot travel (ECOG status 3 or higher, active infection, uncontrolled symptoms)

What to Prepare Before Arrival

• English-language medical records: Pathology reports, imaging (CT/MRI PET scans on disc), PD-L1 test results, and prior treatment history
• PD-L1 expression documentation: If already tested, bring the report. If not, most hospitals can arrange testing upon arrival within 3–5 days
• Treatment history: A clear timeline of prior treatments (surgery, chemotherapy, targeted therapy, prior immunotherapy) with response notes
• Medication list: All current medications including autoimmune drugs, steroids, and supplements — some medications must be tapered before immunotherapy
• Medical visa: Most patients apply for an S1 visa (long-term medical stay, valid 3–12 months, renewable). The hospital provides an invitation letter for the visa application.

Estimated Total Cost for International Patients

• One cycle of immunotherapy (drug + administration): $2,800–$11,500 depending on drug
• One cycle with hospitalization in international ward: $3,500–$13,000
• Full annual course (4–6 cycles): $30,000–$65,000 including monitoring and follow-up
• Flights (round-trip, most international origins): $800–$3,500
• Accommodation (3–6 weeks, mid-range hotel or serviced apartment): $600–$2,500
• Translation and coordinator services: $300–$800 per week
• All-in cost for a full treatment course: $35,000–$75,000 total — still significantly below US costs for equivalent care

Frequently Asked Questions

Is ivonescimab available outside China?

No. As of May 2026, ivonescimab is approved only in China. The FDA and EMA have not approved it. This means it is currently only accessible to patients who travel to China for treatment. The drug's approval was based on the HARMONi-2 Phase III trial conducted entirely in China.

What is the difference between a PD-1 inhibitor and a bispecific antibody like ivonescimab?

A standard PD-1 inhibitor (like pembrolizumab) blocks one target — the PD-1 checkpoint on immune cells. Ivonescimab blocks PD-1 and also binds VEGF, a protein that tumors use to grow new blood vessels. By hitting two targets simultaneously, the drug attacks the tumor's defenses on two fronts at once. This dual mechanism is what produced the superior Phase III results over pembrolizumab alone.

Does China accept international patients for immunotherapy?

Yes. All major Grade 3A hospitals have international patient departments that handle medical records review, treatment planning, interpretation, and admission for overseas patients. English-speaking coordinators are available in most major hospitals. Patients typically submit records remotely before traveling for an initial evaluation and treatment plan.

Can I continue immunotherapy in my home country after starting in China?

In many cases, yes. After the initial cycles in China, subsequent treatments can often be administered at a local hospital in your home country. Your Chinese oncologist can provide a detailed treatment protocol (drug name, dose, infusion schedule, monitoring requirements) that your local oncologist can follow. Some hospitals also offer remote follow-up consultations.

What are the side effects of immunotherapy?

Immunotherapy is generally better tolerated than chemotherapy, but it can cause immune-related adverse events (irAEs). The most common side effects are fatigue, rash, and mild thyroid dysfunction. More serious irAEs — affecting the colon, liver, lungs, or endocrine system — occur in a minority of patients and require prompt treatment with immunosuppressants (typically corticosteroids). Chinese hospitals have established protocols for managing irAEs and monitor bloodwork at each cycle.